Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depressionJournal of Affective Disorders · 2026-11-01The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive DisorderClinicalTrials.gov · 2026-08-13PsiloStudy: A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-08-13Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized TrialClinicalTrials.gov · 2026-08-13Investigating the Effects of Psilocybin on Cognitive Flexibility in Touchscreen and Naturalistic Variations of the Probabilistic Reversal Learning TaskbioRxiv · 2026-08-12TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance TherapyClinicalTrials.gov · 2026-08-12TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer SurvivorsClinicalTrials.gov · 2026-08-12Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use DisorderClinicalTrials.gov · 2026-08-12Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and SuicidalityClinicalTrials.gov · 2026-08-12NeuroGuard: Psilocybin Trial for Preventing Chemo-induced NeuropathyClinicalTrials.gov · 2026-08-12A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety DisorderClinicalTrials.gov · 2026-08-12Psilocybin Recovery Intervention for Stopping Methamphetamine UseClinicalTrials.gov · 2026-08-11A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord InjuryClinicalTrials.gov · 2026-08-10A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsClinicalTrials.gov · 2026-08-10Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study.CNS drugs · 2026-08-07Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand MechanismClinicalTrials.gov · 2026-08-06Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced CancerClinicalTrials.gov · 2026-08-05Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic TherapiesClinicalTrials.gov · 2026-08-04Serotonergic psychedelics induce distinct patterns of metabolic activity and covariance within biologically informed rat brain networksNature Communications · 2026-08-03Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysisJournal of Affective Disorders · 2026-08-01The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysisJournal of Affective Disorders · 2026-08-01Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress DisorderClinicalTrials.gov · 2026-07-30Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical TrialClinicalTrials.gov · 2026-07-28A Systematic Review of EEG Predictors and Correlates of Psilocybin’s Treatment in DepressionUndergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · 2026-07-27A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.ClinicalTrials.gov · 2026-07-23Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND)ClinicalTrials.gov · 2026-07-23A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-07-23A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe AnxietyClinicalTrials.gov · 2026-07-23Longitudinal neural and psychological changes following psilocybin under compassion imagery primingFrontiers in Human Neuroscience · 2026-07-22Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind TrialClinicalTrials.gov · 2026-07-17Psilocybin's effect on human brain synaptic plasticity.Translational psychiatry · 2026-07-15Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled TrialClinicalTrials.gov · 2026-07-14Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the BrainClinicalTrials.gov · 2026-07-10Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)ClinicalTrials.gov · 2026-07-09Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic EffectsClinicalTrials.gov · 2026-07-09Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use DisorderClinicalTrials.gov · 2026-07-09Psilocybin therapy for adult females with anorexia nervosa: pilot studyThe British Journal of Psychiatry · 2026-07-08Synthesis and Biological Evaluation of 4-Bromo-dimethyltryptamine (4-Br-DMT): A Synthetic Building Block for Future Analog Development.ACS omega · 2026-07-07Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone FormulationClinicalTrials.gov · 2026-07-07Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)ClinicalTrials.gov · 2026-07-07Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical DevelopmentBiomolecules · 2026-07-03Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research DirectionsInternational Journal of Eating Disorders · 2026-07-02Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive SymptomsClinicalTrials.gov · 2026-07-01A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-07-01Provider perspectives on challenges in treatment during psychedelic therapy.Psychopharmacology · 2026-07-01Evidence that 5-HT receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.British journal of pharmacology · 2026-07-01Recreational drug poisonings reported to six European poison centres from 2021 to 2024.Clinical toxicology (Philadelphia, Pa.) · 2026-07-01Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participantsNeuropsychopharmacology · 2026-07-01Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical DevelopmentUniversity of Groningen research database (University of Groningen / Centre for Information Technology) · 2026-06-295-HT2A Agonist Psilocybin in the Treatment of Tobacco Use DisorderClinicalTrials.gov · 2026-06-29Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label TrialClinicalTrials.gov · 2026-06-26A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-06-25Multi-metric evaluations of acute psychedelic effects on fMRI brain entropy.Nature communications · 2026-06-24Psilocybin-Assisted Therapy for Prolonged GriefClinicalTrials.gov · 2026-06-23Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and EfficacyClinicalTrials.gov · 2026-06-22Psychedelics relax predictive processing in the post-acute period by remodeling cortico-cortical feedback circuits.bioRxiv: the preprint server for biology · 2026-06-15Psilocybin-assisted Physiotherapy for Refractory Motor Functional Neurological Disorder: A Randomized Dose-comparison Pilot Study (P7-17.001)Neurology · 2026-06-09A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's DiseaseClinicalTrials.gov · 2026-06-08Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled StudyClinicalTrials.gov · 2026-06-04Acute Hallucinogen Intoxication Following Ingestion of a Commercially Available Mushroom Extract Product: A Case Report.Cureus · 2026-06-01Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depressionJournal of Affective Disorders · 2026-06-01Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trialJournal of Affective Disorders · 2026-06-01Psilocybin-induced neurocardiogenic syncope: a case reportPsychopharmacology · 2026-05-28Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b TrialPsychotherapy and Psychosomatics · 2026-05-27Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorderTranslational Psychiatry · 2026-05-26Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot TrialClinicalTrials.gov · 2026-05-22Psilocybin-assisted Cognitive Behavioral Therapy for DepressionClinicalTrials.gov · 2026-05-19Psilocybin-facilitated Treatment for Cocaine UseClinicalTrials.gov · 2026-05-18Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major DepressionJAMA Network Open · 2026-05-15Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner ViolenceClinicalTrials.gov · 2026-05-14Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal IdeationThe Journal of Clinical Psychiatry · 2026-05-13Psilocybin for Treatment of Obsessive Compulsive DisorderClinicalTrials.gov · 2026-05-12Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based SampleClinicalTrials.gov · 2026-05-12A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderClinicalTrials.gov · 2026-05-12The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.ClinicalTrials.gov · 2026-05-081080 Psilocybin Elicits Non-Linear Night to Night Changes in Sleep Spectral PowerSLEEPJ · 2026-05-08Neural correlates of insight on psilocybin: a within-subjects, healthy volunteer studyJoCN Forum · 2026-05-08A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With CancerClinicalTrials.gov · 2026-05-06Human brain changes after first psilocybin useNature Communications · 2026-05-05A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-ControlClinicalTrials.gov · 2026-05-04Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive DisorderClinicalTrials.gov · 2026-05-04Effects of Psilocybin Treatment on Cognitive Effort Avoidance in Major Depressive Disorder and Co-Occurring Alcohol Use DisorderJoCN Forum · 2026-05-02Acute Effects of 4-Bromo-2,5-Dimethoxyphenethylamine (2C-B) Compared With Psilocybin and MDMA in Healthy ParticipantsBiological Psychiatry · 2026-05-01The helioscope effect: A new framework for evaluating trauma-related memory processing in psychedelic experiences.Journal of psychopharmacology (Oxford, England) · 2026-05-01Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms.Journal of affective disorders · 2026-05-01Insights into psilocybin use among people with bipolar disorder: A thematic analysis of Reddit postsJournal of Affective Disorders · 2026-05-01Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanismsNeuropharmacology · 2026-05-01Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.Journal of psychopharmacology (Oxford, England) · 2026-05-01Trends in first-time psychedelic and other hallucinogen use in the United States: Results from the National Survey on Drug Use and Health.Drug and alcohol dependence · 2026-05-01Efficacy and Safety of Psilocybin in Treatment-Resistant Major DepressionJAMA Psychiatry · 2026-05-01Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUMBJPsych Open · 2026-05-01Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled SettingsRepository for Publications and Research Data (ETH Zurich) · 2026-04-30Psilocybin use among Basotho healers and non-healers in southern AfricaOSF Preprints · 2026-04-23Psilocybin-Enhanced Psychotherapy for Methamphetamine Use DisorderClinicalTrials.gov · 2026-04-22A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-04-22Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted PsychotherapyClinicalTrials.gov · 2026-04-22Psychedelics: Historical Context, Emerging Science, and Future Clinical FrontiersJournal of Mental Health Disorders · 2026-04-18CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical TrialClinicalTrials.gov · 2026-04-13Severe Illness Associated with Eating Mushroom-Containing Chocolate Products - United States, January-October 2024.MMWR. Morbidity and mortality weekly report · 2026-04-08Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use DisorderClinicalTrials.gov · 2026-04-07Effects of Psilocybin in Obsessive Compulsive DisorderClinicalTrials.gov · 2026-04-02Psilocybin: Wirksam, aber kein WundermittelMMW - Fortschritte der Medizin · 2026-04-01Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocolsEuropean Neuropsychopharmacology · 2026-04-01PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial.Palliative medicine · 2026-04-01An international mega-analysis of psychedelic drug effects on brain circuit function.Nature medicine · 2026-04-01Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations.Expert opinion on pharmacotherapy · 2026-04-01Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness-a psychometric analysis using the PES100 in controlled psychedelic studiesReligion Brain & Behavior · 2026-03-31Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in DepressionClinicalTrials.gov · 2026-03-30Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use DisorderClinicalTrials.gov · 2026-03-30Associations Between Psilocybin Use Motives and Cognitive, Affective, and Behavioural Self-StigmaSubstance Use & Misuse · 2026-03-28Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory DepressionClinicalTrials.gov · 2026-03-27The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.ClinicalTrials.gov · 2026-03-24Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging TrialClinicalTrials.gov · 2026-03-24Psychedelics in functional disorders: A scoping review.Progress in neuro-psychopharmacology & biological psychiatry · 2026-03-20Pilot Study of Psilocybin-assisted Treatment for Cannabis Use DisorderClinicalTrials.gov · 2026-03-18Synthesis and Characterization of Psilocybin Metabolites and Deuterated AnalogsACS Chemical Neuroscience · 2026-03-18Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use DisorderClinicalTrials.gov · 2026-03-13Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept StudyClinicalTrials.gov · 2026-03-11Oregon's Emerging Psilocybin Services Workforce: A Survey of the First Legal Psilocybin Facilitators and Their Training ProgramsPsyArXiv · 2026-03-11Discovery of the closest free-living relative of the domesticated 'magic mushroom' Psilocybe cubensis in Africa.Proceedings. Biological sciences · 2026-03-11Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders.CNS & neurological disorders drug targets · 2026-03-11Age moderates the relationship between psychedelics use and mental health in naturalistic settingsResearch Square · 2026-03-10Behavioural investigations of psilocybin in non-human animals 1962-2021: A scoping reviewJournal of Psychedelic Studies · 2026-03-09Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept TrialClinicalTrials.gov · 2026-03-04A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.ClinicalTrials.gov · 2026-03-03Psilocybin Reshapes Anterior Cingulate Network Neuropathic Topology to Reduce Chronic PainThe Journal of Pain · 2026-03-01Meaning and Psychedelics in Palliative Care: A Narrative Review.Journal of pain and symptom management · 2026-03-01Early response to psilocybin in adults with treatment-resistant depression as a predictor for antidepressant efficacyGeneral Hospital Psychiatry · 2026-03-01Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review.Psychedelic medicine (New Rochelle, N.Y.) · 2026-03-01Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applicationsProgress in Neuro-Psychopharmacology and Biological Psychiatry · 2026-03-01Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy.BMJ supportive & palliative care · 2026-02-27Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind TrialClinicalTrials.gov · 2026-02-23Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical TrialResearch Square · 2026-02-23Rebuttal to "Questioning the recovery of dissociated traumatic memories under psilocybin".Journal of eating disorders · 2026-02-17Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial.BJPsych open · 2026-02-16Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical TrialClinicalTrials.gov · 2026-02-12Psilocybin-Assisted Cognitive Behavioral Therapy for DepressionClinicalTrials.gov · 2026-02-12Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCDPsyArXiv · 2026-02-11Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy VolunteersClinicalTrials.gov · 2026-02-05Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER: a Pilot StudyClinicalTrials.gov · 2026-02-05India's Unique Legal Framework for Psilocybin Mushroom Research: An Unprecedented Opportunity in Psychiatric Therapeutics.Indian journal of psychological medicine · 2026-02-05Compassionate use of psilocybin for treatment-resistant depression in Germany.The lancet. Psychiatry · 2026-02-01Psilocybin use in bipolar disorder: A comprehensive review.Journal of affective disorders · 2026-02-01Pharmacodynamic biomarker - or psychotherapeutic process? Comment on "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression".Journal of affective disorders · 2026-02-01Psilocybin and Bipolar Depression: Promise and Prudence.CNS drugs · 2026-02-01Bioactive compounds from Psilocybe cubensis mycelial cultures with transient anxiolytic effects in mice.Journal of physiology and pharmacology: an official journal of the Polish Physiological Society · 2026-02-01Psychedelic research and sexuality: opportunities and pitfallsThe Journal of Sexual Medicine · 2026-01-28The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidenceZenodo (CERN European Organization for Nuclear Research) · 2026-01-26A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone TreatmentClinicalTrials.gov · 2026-01-23Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.Open Access CRIS of the University of Bern · 2026-01-21Psilocybin for Treatment-Resistant OCD: A Randomized Controlled TrialPsyArXiv · 2026-01-15Neuroscience: What doesn't kill you makes you stronger.Current biology: CB · 2026-01-05An open-label pilot study of psilocybin-assisted therapy for binge eating disorder.Journal of eating disorders · 2026-01-03Daily Administration of Psilocin Mucate (L-130) Produces a Favorable Safety Profile and Anxiolytic Effects in Rodents Exposed to Chronic Unpredictable Mild StressJournal of Psychoactive Drugs · 2026-01-02Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.JAMA network open · 2026-01-02Psychedelic DrugsIntechOpen · 2026-01-01Facing Mortality Together: A Constructivist Grounded Theory Analysis of Group Psilocybin Therapy Among Older Long-Term AIDS Survivor Gay MenPalliative Medicine Reports · 2026-01-01Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE): Results of a randomized active placebo-controlled trialNeuroscience Applied · 2026-01-01Relationship between cardiovascular effects and psychedelic experiences under psilocybin in patients with treatment-resistant depressionNeuroscience Applied · 2026-01-01Attitudes Toward Psychedelic Treatments by Individuals With Histories of Substance Use or Psychiatric Disorders: A Survey Study.Journal of addiction medicine · 2026-01-01Psychedelic Drug Checking: Analytical and Strategic Challenges in Harm Reduction for Classic Psychedelics.Current topics in behavioral neurosciences · 2026-01-01A novel psychedelic 5-HT receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer.Journal of psychopharmacology (Oxford, England) · 2026-01-01Indigenous Knowledge Systems & Psychedelic Science: Towards Ethical and Reciprocal Collaboration.Journal of psychopharmacology (Oxford, England) · 2026-01-015 Years of bipolar disorder conversations on Reddit: Methods, key topics and future directions.PloS one · 2026-01-01Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling.Therapeutic advances in drug safety · 2026-01-01Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians.Therapeutic advances in psychopharmacology · 2026-01-01Effects of Serotonergic Psychedelics on Synaptic Function and NeuroplasticityOPUS FAU - Online publication system of Friedrich-Alexander-Universität Erlangen-Nürnberg · 2025-12-31Microdosing Psychedelics to Improve MoodClinicalTrials.gov · 2025-12-30An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality DisorderClinicalTrials.gov · 2025-12-23Effects of LSD and Psilocybin on Heart Rate in Patients Receiving Psychedelic Treatment for Depressive and Anxiety Disorders: A Retrospective Observational StudyPsychology International · 2025-12-19The Role of Touch in Psychedelic Therapy: Perspectives From a Survey of Practitioners in Research Settings.American journal of psychotherapy · 2025-12-15Are Magic Mushrooms the Magic to Healing?DigitalCommons - Kennesaw State University (Kennesaw State University) · 2025-12-07Questioning the recovery of dissociated traumatic memories under psilocybin: comment on "Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa".Journal of eating disorders · 2025-12-04Psilocybin-assistierte Gruppenpsychotherapie bei AbhängigkeitserkrankungenOpen Access CRIS of the University of Bern · 2025-12-01Psychedelics for the Treatment of Substance Use DisordersSUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · 2025-12-01Meaning and Purpose Therapy Modified for Psilocybin (P-MaP): A Treatment Model for Palliative Care PatientsJournal of Health Service Psychology · 2025-12-01Three Cases of Depersonalization/Derealization Disorder Related to the Use of Classic PsychedelicsSUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · 2025-12-01Psilocybin as a fast-acting and long-lasting antidepressant for adolescence: Proposing NeuroD1 as a biomarker of its long-term plasticity.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025-12-01Persistent Altered States: Psychological Treatment of Psychedelic Adverse EffectsTidsskrift for Norsk psykologforening · 2025-11-30Psilocybin vs Ketamine for Alcohol Use DisorderClinicalTrials.gov · 2025-11-28Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive DisorderClinicalTrials.gov · 2025-11-26Self-reported improvement in depression, anxiety, and substance use in Spanish-speakers after a memorable psychedelic experiencePsychedelics · 2025-11-20Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.ClinicalTrials.gov · 2025-11-19Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use DisorderClinicalTrials.gov · 2025-11-17Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover TrialPsyArXiv · 2025-11-16Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study.Journal of affective disorders · 2025-11-15Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders.Journal of psychoactive drugs · 2025-11-10Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch NegativitybioRxiv · 2025-11-07Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigmUniversität Zürich, ZORA · 2025-11-05Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive DisorderClinicalTrials.gov · 2025-11-05Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study.Acta neuropsychiatrica · 2025-11-04[Acceptance of psilocybin-assisted therapy in German-speaking countries].Der Nervenarzt · 2025-11-01Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis.International journal of psychiatry in medicine · 2025-11-01Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds.EClinicalMedicine · 2025-11-01Psychedelic 5-HT receptor agonism alters neurovascular coupling and differentially affects neuronal and hemodynamic measures of brain function.Nature neuroscience · 2025-11-01Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applicationsCaderno Pedagógico · 2025-10-31A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?ClinicalTrials.gov · 2025-10-29Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial.Pilot and feasibility studies · 2025-10-28Home-based psilocybin-assisted therapy for a patient with advanced cancer: A case report.Palliative & supportive care · 2025-10-23